Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegenerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

Abstract: Compounds having Formula I or II, and methods of making and using thereof, are described herein:

Abstract: A process for designing of PCR-based detection method for Chlamydia trachomatis comprising designing of PCR primers from the genome sequence of Chlamydia trachomatis selecting DNA sequence of genes for PCR based diagnostic of Chlamydia trachomatis, optimizing the PCR conditions of the PCR primers; subjecting the said genes and primers to the step of characterization.

Abstract: Compounds having Formula I or II, and methods of making and using thereof, are described herein:

Abstract: The present invention provides Withania somnifera plant extract and composition comprising the extract useful for the treatment of neurodegenerative disease and/or disorders such as Alzheimers disease (AD). The present invention further provides a process for preparation of the extract.

Abstract: A cytoplasmic male sterility (CMS) system in different Brassica species having a distinct mitochondrial DNA specific RFLP signature. A method for obtaining male sterile lines and restoration of fertility in B. juncea for hybrid seed production using the CMS. This CMS in B. juncea can be restored by crossing male sterile plants with any B. juncea genotype other than the maintainer genotype. The same B. juncea genotype acts as maintainer of male sterility after a specified number of backcrosses. The CMS also relates to histological characterization of another and microspore development in B. juncea.

Abstract: The present invention provides mutant Mycobacterium strains harboring a modified tyrosine phosphatase gene (mptpA or mptpB) wherein the mutant Mycobacterium strain is incapable of expressing the active tyrosine phosphatase. The invention provides a method for developing the said mutant strain from either Mycobacterium tuberculosis or Mycobacterium bovis. The mptpA or mptpB gene may be modified by replacing the internal sequences with an antibiotic resistance marker gene, which disrupts the expression of the active gene. The invention further provides a recombinant vector comprising the modified mptpA or mptpB which may be used to develop the mutant strains of mycobacteria. The invention provides a method to assess the role of tyrosine phosphatases MptpA and MptpB in the virulence and pathogenesis of Mycobacterium which can be used as potential targets for developing anti-tubercular drug.

Abstract: A method for obtaining improved fertility restorer lines for male sterile crop plants and a DNA construct for use in said method are disclosed. The invention relates to the simultaneous use of two different gene sequences encoding the same protein product, one being the naturally occurring wild type sequence and the other sequence being generated by modification of the wild type sequence for expression in crop plants by using codon degeneracy to avoid homology between the two sequences at the DNA and mRNA levels, each of the said sequences being placed under independent transcriptional control of different overlapping plant tissue-specific regulatory elements in the same DNA construct.

Abstract: The present invention relates to isolation and characterization of novel nucleotide sequences from rice tungro bacilliform virus (RTBV) showing promoter activity in plants. The present invention further relates to the analysis of the functional domains of RTBV promoters by fusing full-length and deleted versions of the RTBV promoter sequences with the bacterial reporter gene GUS. The invention also relates to the study of the expression of the reporter gene in various tissues of transgenic rice and tobacco plants during different stages of development. The present invention also describes an RTBV promoter and its deletions which function in a constitutive or tissue-specific manner to drive the expression of the heterologous nucleic acid sequences in both monocot and dicot plants, cells and tissues.

Abstract: The present invention provides mutant Mycobacterium strains harboring a modified tyrosine phosphatase gene (mptpA or mptpB) wherein the mutant Mycobacterium strain is incapable of expressing the active tyrosine phosphatase. The invention provides a method for developing the said mutant strain from either Mycobacterium tuberculosis or Mycobacterium bovis. The mptpA or mptpB gene may be modified by replacing the internal sequences with an antibiotic resistance marker gene, which disrupts the expression of the active gene. The invention further provides a recombinant vector comprising the modified mptpA or mptpB which may be used to develop the mutant strains of mycobacteria. The invention provides a method to assess the role of tyrosine phosphatases MptpA and MptpB in the virulence and pathogenesis of Mycobacterium which can be used as potential targets for developing anti-tubercular drug.

Abstract: The present invention relates to identification, isolation, characterization and use of a novel gene OSISAP1 obtained from rice and its corresponding novel protein sequence; also relates to a method of over-expressing the novel gene OSISAP1 encoding a zinc-finger stress associated protein from rice conferring salt, cold and drought stress tolerance in transgenic plant systems, further this invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing the novel gene OSISAP1 and a method of producing such plants and plant seeds.

Abstract: The present invention relates to a process of obtaining recombinant lambdoid bacteriophage with high density display of functional peptides and proteins on surface of said phage comprising of: constructing a donor plasmid having a nucleotide sequence that defines the elements for replication of the vector in bacteria, a selectable marker, a nucleotide sequence flanked by two non-compatible recombination sequences, and an inducible cistron for expression of a capsid protein and a fusion protein; constructing a recipient phage having a nucleotide sequence that defines the lambdoid elements for replication and packaging of the vector into an assembled bacteriophage and encodes an inducible cistron for expression of a selectable marker flanked by two non-compatible recombination sequences; transferring the said donor plasmid to said recipient plasmid to obtain cointegrates; growing said cointegrates in selective liquid medium; harvesting phages displaying protein encoded by the foreign DNA encapsulated in said ha

Abstract: The present invention relates to a novel cytoplasmic male sterility (CMS) ‘126-1’ system in different Brassica species and a method for obtaining male sterile lines using the said CMS. The CMS has distinct mitochondrial DNA specific RFLP signature. The invention also relates to a method for obtaining male sterile lines and restoration of fertility in B. juncea for hybrid seed production. This CMS in B. juncea can be restored by crossing male sterile plants with any B. juncea genotype other than the maintainer genotype. The same B. juncea genotype acts as maintainer of male sterility after a specified number of backcrosses. This invention also relates to the histological characterization of anther and microspore development in B. juncea.

Abstract: The present invention relates to an Insulator construct for controlling leaky expression of a lethal gene from enhancing functions of a strong constitutive promoter present in the said Insulator construct following integration into the genome of a plant and a method for development of male sterile lines in crop plants using the said Insulator construct.

Abstract: The present invention relates to sustained release and long residing opthalmic formulation having thermosensitivity, mucoadhesiveness, hydro gel properties and small particle size. The said formulation comprises micelle solution of random block co-polymer having a hydrophobic component and a hydrophillic component of general formula —(X+Y+Z-)m, and at least one hydrophobic drug with the block co-polymer solution. The invention also provides a process of preparing said formulation.

Abstract: The present invention relates to a process of entrapping genetic materials in nanoparticles of inorganic metal salts of size below 100 nm diameter to form non-viral carriers for delivery of genes. The process comprises the steps of dissolving surfactants and a cosurfactant in oil to obtain reverse micelles. An aqueous solution of genetic material is added to the reverse micelles. Thereafter the reverse micelles are divided into two equal parts. To one part, aqueous solution of inorganic metal salts is dissolved to obtain optically clear and transparent reverse micelles. To the second part aqueous solution of precipitating agent is added to obtain optically clear and transparent reverse micelles. The two equally divided parts of reverse micelles are mixed to form inorganic nanopartcles encapsulating added genetic material. Thereafter, the nanoparticles are separated from reverse micelles, the inorganic nanoparticles are dispersed in water and dialyzed to remove free metal salts, surfactant and oil.

Abstract: The present invention relates to a process of entrapping genetic materials in nanoparticles of inorganic metal salts of size below 100 nm diameter to form non-viral carriers for delivery of genes. The process comprises the steps of dissolving surfactants and a cosurfactant in oil to obtain reverse micelles. An aqueous solution of genetic material is added to the reverse micelles. Thereafter the reverse micelles are divided into two equal parts. To one part, aqueous solution of inorganic metal salts is dissolved to obtain optically clear and transparent reverse micelles. To the second part aqueous solution of precipitating agent is added to obtain optically clear and transparent reverse micelles. The two equally divided parts of reverse micelles are mixed to form inorganic nanoparticles encapsulating added genetic material. Thereafter, the nanoparticles are separated from reverse micelles, the inorganic nanoparticles are dispersed in water and dialyzed to remove free metal salts, surfactant and oil.